Register for our free email digests:
IOmet Pharma Ltd.
Division of Merck & Co. Inc.
iometpharma.com
Latest From IOmet Pharma Ltd.
BIO Notebook, Day 4: Annual Convention Winds Down With Oncology In The Spotlight
Oncology was top of mind for Scrip on the final day of the BIO International Convention in San Diego, including a next-generation cancer drug panel discussion and interviews with novel therapeutic developers. A day earlier, we spoke with Merck & Co about deals related to Keytruda and beyond.
Scrip's Rough Guide To IDO
IDO has emerged at the lead suitor among new cancer immunotherapy targets to partner with PD-1/L1 inhibitors; the early data help show why big pharmas are so much on board.
Biopharma Quarterly Dealmaking Statistics, Q1 2016
Q1 biopharma financing totaled $5.7 billion, a sharp drop from Q4, but this time early-stage venture rounds were the most popular fundraising vehicle;Q1 M&A also declined, totaling $12.3 billion, mostly from Mylan's $9.9 billion buy of Meda. The top alliance was again by Sanofi, in a five-year potential $2.26 billion collaboration with DiCE Molecules to develop oral small-molecule therapies against up to 12 targets.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Therapeutic Areas
- Cancer
- Alias(es)
- Ownership
- Private
- Headquarters
-
Worldwide
-
Europe
-
Western Europe
-
UK
-
UK
-
Western Europe
-
Europe
- Parent & Subsidiaries
- Merck & Co. Inc.
- Senior Management
-
Alan Wise, PhD, CEO
Peter Trill, CFO - Contact Info
-
IOmet Pharma Ltd.
Nine Edinburgh BioQuarter
Little France
Edinburgh, EH16 4UX
UK
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice